Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Jun 15, 2022; 14(6): 1086-1102
Published online Jun 15, 2022. doi: 10.4251/wjgo.v14.i6.1086
Published online Jun 15, 2022. doi: 10.4251/wjgo.v14.i6.1086
Professional organization | Recommended ages for screening | Other considerations |
American College of Gastroenterology (2021) | 50-75 | Screening after age 75 should be considered on an individualized basis; providers must engage in shared decision making |
United States Preventive Services Task Force (2021) | 45-75 | Screening adults aged 76-85 should be conducted on an individualized basis; do not screen adults age 86 years and above |
United States Multi-Society Task Force on Colorectal Cancer (2021) | 45-75 | Consider discontinuation when persons up to date with screening, who have prior negative screening reach age 75 or have < 10 yr of life expectancy. Persons without prior screening should be considered for screening up to age 85, depending on age and comorbidities. |
Canadian Task Force on Preventive Health Care (2016) | 50-74 | Recommend not screening adults aged 75 yr and older. (Weak recommendation; low-quality evidence) |
American College of Physicians (2019) | 50-75 | Discontinue screening in average-risk adults older than 75 yr or in adults with a life expectancy of 10 yr or less |
American Cancer Society (2018) | 45-75 | Screening adults aged 76-85 should be conducted on an individualized basis; screening discouraged above age 85 |
Condition | Value | Score |
Age | < 50, 50-59, 60-69, 70-79, 80+ | 0, +1, +2, +3, +4 |
Myocardial infarction | Yes/no | +1 |
CHF | Yes/no | +1 |
PVD | Yes/no | +1 |
CVA or TIA | Yes/no | +1 |
Dementia | Yes/no | +1 |
COPD | Yes/no | +1 |
Connective tissue disease | Yes/no | +1 |
Peptic ulcer disease | Yes/no | +1 |
Liver disease | None/mild/severe | +1 (mild), +3 (moderate-severe) |
Diabetes mellitus | None or diet controlled /uncomplicated/end-organ damage | +1 (uncomplicated), +2 (end-organ damage) |
Hemiplegia | Yes/no | +2 |
CKD | Yes/no | +2 |
Solid tumor | None/localized/metastatic | +2 (local), +6 (metastatic) |
Leukemia | Yes/no | +2 |
Lymphoma | Yes/no | +2 |
AIDS | Yes/no | +6 |
Risk | Associated problems | Mitigation |
Perforation | Bleed, infection, necrotic bowel | Endoscopic technique (carbon dioxide insufflation, use of pediatric endoscopic equipment, careful navigation of diverticular disease), adequate bowel preparation |
Bleeding | Post-polypectomy bleed | Hemoclip placement for bleeding prevention when appropriate, diluted epinephrine injection, use of detachable snare, thermal coagulation |
Cardiovascular event | Arrythmia | Medication review, screen for high-risk medications, confirm dosing appropriate for renal function; adjustment of anesthesia |
Anticoagulation therapy interruption | Risk of thrombosis, MI, CVA | Liaise with prescribing physician; avoid colonoscopy during high-risk period; avoid interruption if possible |
Delirium | Cognitive impairment | Risk assessment; optimize medication list, avoid holding medications with withdrawal potential on morning of procedure |
Medication interaction | Polypharmacy increases sensitivity to anesthesia | Medication review; adjustment of anesthesia |
Dehydration | Electrolyte disturbances | Appropriate counseling prior to colonoscopy prep; caretaker supervision to ensure patient safety during prep |
- Citation: Gornick D, Kadakuntla A, Trovato A, Stetzer R, Tadros M. Practical considerations for colorectal cancer screening in older adults. World J Gastrointest Oncol 2022; 14(6): 1086-1102
- URL: https://www.wjgnet.com/1948-5204/full/v14/i6/1086.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i6.1086